Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer

International Journal of Clinical Practice

Volumn 69, Issue 1, 2015, Pages 106-123

  White, I D ^a   Wilson, J ^b   Aslet, P ^c   Baxter, A B ^a   Birtle, A ^d   Challacombe, B ^e   Coe, J ^f   Grover, L ^g   Payne, H ^f   Russell, S ^h   Sangar, V ⁱ   Van As, N ^a   Kirby, M ^j,k  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e GUY S HOSPITAL   (United Kingdom)

^f ROYAL LONDON HOSPITAL   (United Kingdom)

^g London Clinic Cancer Centre   (United Kingdom)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j Prostate Centre   (United Kingdom)

^k UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; CANCER RADIOTHERAPY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COUNSELING; DRUG EFFICACY; ERECTILE DYSFUNCTION; HEALTH PROGRAM; HUMAN; LIFESTYLE MODIFICATION; MEDICAL DEVICE; NATIONAL HEALTH SERVICE; PELVIC FLOOR MUSCLE TRAINING; PROSTATE CANCER; PROSTATECTOMY; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SEXUALITY; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; UNITED KINGDOM; VACUUM ERECTION DEVICE; ADVERSE EFFECTS; MALE; PRACTICE GUIDELINE; PROSTATIC NEOPLASMS; RADIOTHERAPY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ERECTILE DYSFUNCTION; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; UNITED KINGDOM;

EID: 84920774722     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12512     Document Type: Review

References (72)

1. Cancer research UK website. http://info.cancerresearchuk.org/cancerstats/index.htm (accessed April 2014).
2. Bokhour BG, Clark JA, Inui TS, Silliman RA, Talcott JA,. Sexuality after treatment for early prostate cancer: exploring the meanings of "erectile dysfunction". J Gen Intern Med 2001; 16: 649-55.
3. National Institute for Health and Care Excellence. CG175 Prostate cancer, 2014. http://guidance.nice.org.uk/CG175/NICEGuidance/pdf/English (accessed May 2014).
4. British Uro-Oncology Group. Multi-disciplinary team (MDT) guidance for managing prostate cancer. http://www.bug.uk.com/publications.php, September 2013 (accessed April 2014).
5. Sountoulides P, Rountos T,. Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. ISRN Urol 2013; 2013: 1-8.
6. Candy B, Jones L, Williams R, Tookman A, King M,. Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review. BJU Int 2008; 102 (4): 426-31.
7. Miles CL, Candy B, Jones L, Williams R, Tookman A, King M,. Interventions for sexual dysfunction following treatments for cancer. Cochrane Database Syst Rev 2007; 4: CD005540.
8. Meuleman EJ, Mulders PF,. Erectile function after radical prostatectomy: a review. Eur Urol 2003; 43: 93-102.
9. Wittmann D, Montie JE, Hamstra DA, Sandler H, Wood DP Jr,. Counseling patients about sexual health when considering post-prostatectomy radiation treatment. Int J Impot Res 2009; 21 (5): 275-84.
10. Stember DS, Mulhall JP,. The concept of erectile function preservation (penile rehabilitation) in the patient after brachytherapy for prostate cancer. Brachytherapy 2012; 11 (2): 87-96.
11. Mulhall J, Ahmed Aarker M, Mohideen N,. The hemodynamics of erectile dysfunction following external beam radiation for prostate cancer. J Sex Med 2005; 2 (3): 432-7.
12. Merrick GS, Butler WM, Wallner KE, et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 2002; 4: 1055e1062.
13. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-82.
14. Mazzola CR, Mulhall JP,. Impact of androgen deprivation therapy on sexual function. Asian J Androl 2012; 14 (2): 198-203.
15. Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW,. Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. J Sex Med 2010; 7: 2996-3010.
16. Marumo K, Baba S, Murai M,. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Int J Urol 1999; 6: 19-23.
17. Tal R, Mueller A, Mulhall JP,. The correlation between intracavernosal pressure and cavernosal blood oxygenation. J Sex Med 2009; 6: 2722-7.
18. Hagedoorn M, Sanderman R, Bolks HN, Tuinstra J, Coyne JC,. Distress in couples coping with cancer: a meta-analysis and critical review of role and gender effects. Psychol Bull 2008; 134: 1-30.
19. Soloway CT, Soloway MS, Kim SS, Kava BR,. Sexualsychological and dyadic qualities of the prostate cancer 'couple'. BJU Int 2005; 95: 780-5.
20. Sharifi N, Gulley JL, Dahut WL,. Androgen deprivation therapy for prostate cancer. J Am Med Assoc 2005; 294: 238-44.
21. Grossmann M, Zajac JD,. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf) 2011; 74 (3): 289-93.
22. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-83.
23. Smith MR, Lee H, Nathan DM,. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-8.
24. Galvão DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008; 102: 44-7.
25. Galvão DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU,. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 2009; 12: 198-203.
26. Roayaei M, Ghasemi S,. Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer. J Res Med Sci 2013; 18 (7): 580-2.
27. DiBlasio CJ, Hammett J, Malcolm JB, et al. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. Can J Urol 2008; 15: 4249-56, discussion 4256.
28. Elliott J, Fallows A, Staetsky L, et al. The health and well-being of cancer survivors in the UK: findings from a population-based survey. Br J Cancer 2011; 105 (Suppl. 1): S11-20.
29. Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19 (17): 3750-7.
30. Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW,. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1235-42.
31. Haliloglu A, Baltaci S, Yaman O,. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer. J Urol 2007; 177 (1): 128-30.
32. Higano CS,. Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. J Clin Oncol 2012; 30 (30): 3720-5.
33. DiBlasio CJ, Malcolm JB, Derweesh IH, et al. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int 2008; 102 (1): 39-43.
34. Budäus L, Bolla M, Bossi A, et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 2012; 61 (1): 112-27.
35. Kirby MG, White ID, Butcher J, et al. Development of UK recommendations on treatment for post-surgical erectile dysfunction. Int J Clin Pract 2014; 68 (5): 590-608.
36. Oxford Centre for Evidence-based Medicine-levels of evidence. http://www.cebm.net/index.aspx?o=1025 (accessed April 2014).
37. Zelefsky MJ, Shasha D, Branco RD, et al. Prophylactic sildenafil citrate for improvement of erectile function in men treated by radiotherapy for prostate cancer. J Urol 2014; Mar 3 [Epub ahead of print].
38. Ilic D, Hindson B, Duchesne G, Millar JL,. A randomised, double-blindlacebo-controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. J Med Imaging Radiat Oncol 2013; 57 (1): 81-8.
39. Yang L, Qian S, Liu L, et al. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: a systematic review and meta-analysis. Urol Int 2013; 90 (3): 339-47.
40. Watkins-Bruner D, James JL, Bryan CJ, et al. Randomized, double-blindedlacebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J Sex Med 2011; 8 (4): 1228-38.
41. Pahlajani G, Raina R, Jones JS, et al. Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. BJU Int 2010; 106 (10): 1524-7.
42. Ricardi U, Gontero P, Ciammella P, et al. Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. J Sex Med 2010; 7 (8): 2851-9.
43. Teloken PEarker M, Mohideen N, Mulhall JP,. Predictors of response to sildenafil citrate following radiation therapy for prostate cancer. J Sex Med 2009; 6 (4): 1135-40.
44. Incrocci L, Slob AK, Hop WC,. Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial. Urology 2007; 70 (6): 1190-3.
45. Teloken PE, Ohebshalom M, Mohideen N, Mulhall JP,. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol 2007; 178 (6): 2521-5.
46. Incrocci L, Slagter C, Koos Slob A, Hop WCJ,. A randomised, double-blindlacebo-controlled, cross-over study to assess the efficacy of Tadalafil in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Rad Oncol 2006; 66: 439-44.
47. Schiff JD, Bar-Chama N, Cesaretti J, Stock R,. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU Int 2006; 98 (6): 1255-8.
48. Ohebshalom Marker M, Guhring P, Mulhall JP,. The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations. J Urol 2005; 174 (1): 258-62.
49. Incrocci L, Hop WCJ, Slob KA,. Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer. Urology 2003; 62 (1): 116-20.
50. Incrocci L, Koper PCM, Hop WCJ, Slob K,. Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double blindlacebo-controlled, cross-over study. Int J Rad Oncol Biol Physiol 2001; 5 1(5): 1190-5.
51. Forbat L, White I, Marshall-Lucette S, Kelly D,. Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer. BJU Int 2012; 109 (1): 98-103.
52. Canada AL, Neese LE, Sui D, Schover LR,. Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer 2005; 104: 2689-700.
53. Cormie P, Newton RU, Taaffe DR, et al. Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial. Prostate Cancer Prostatic Dis 2013; 16 (2): 170-5.
54. Lepore SJ, Helgeson VS, Eton DT, Schulz R,. Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions. Health Psychol 2003; 22 (5): 443-52.
55. Hartmann U, Burkart M,. Erectile dysfunctions in patient-physician communication: optimized strategies for addressing sexual issues and the benefit of using a patient questionnaire. J Sex Med 2007; 4 (1): 38-46.
56. Tombal B,. A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient. Urol Int 2009; 83: 373-8.
57. Johnson ME, Buyyounouski MK,. Androgen deprivation therapy toxicity and management for men receiving radiation therapy. Prostate Cancer 2012; 2012: 580306.
58. Jannini EA, Screponi E, Carosa E, et al. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl 1999; 22: 385-92.
59. Bourke L, Kirkbride P, Hooper R, Rosario AJ, Chico TJ, Rosario DJ,. Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? Br J Cancer 2013; 108 (1): 9-13.
60. Ahn HSark CM, Lee SW,. The clinical relevance of sex hormone levels and sexual activity in the ageing male. BJU Int 2002; 89: 526-30.
61. Martinez-Jabaloyas JM, Queipo-Zaragoza Aastor-Hernandez F, Gil-Salom M, Chuan-Nuez P,. Testosterone levels in men with erectile dysfunction. BJU Int 2006; 97: 1278-83.
62. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363 (2): 123-35.
63. Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC,. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000; 164: 1891-4.
64. Gulley JL, Figg WD, Steinberg SM, et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005; 173: 1567-71.
65. Bong GW, Clarke HS Jr, Hancock WC, Keane TE,. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology 2008; 71: 1177-80.
66. Wilke DRarker C, Andonowski A, et al. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists. BJU Int 2006; 97 (5): 963-8.
67. Traish AMark K, Dhir V, Kim NN, Moreland RB, Goldstein I,. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999; 140 (4): 1861-8.
68. Isidori AM, Buvat J, Corona G, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol 2014; 65 (1): 99-112.
69. Welliver RC Jr, Mechlin C, Goodwin B, Alukal JP, McCullough AR,. A pilot study to determine penile oxygen saturation before and after vacuum therapy in patients with erectile dysfunction after radical prostatectomy. J Sex Med 2014; 11 (4): 1071-7.
70. Ahmadi H, Daneshmand S,. Androgen deprivation therapy: evidence-based management of side effects. BJU Int 2013; 111 (4): 543-8.
71. Hackett G, Kell P, Ralph D, et al.; British Society for Sexual Medicine. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med 2008; 5: 1841-65.
72. National Institute for Health and Care Excellence. CG58 Prostate cancer: diagnosis and management.